You are here

Europe

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

Pharmaforum

BRCA-mutant breast cancer

Flag link:

After falling short on prelim OS data, EMA tells Aveo it wants to see something better on its long suffering tivo this summer — or else

After falling short on prelim OS data, EMA tells Aveo it wants to see something better on its long suffering tivo this summer — or else

Endpoints

Flag link:

Teva wins EU nod for Ajovy migraine prophylactic

Teva wins EU nod for Ajovy migraine prophylactic

Drug Delivery Business News

Teva Pharmaceutical

Flag link:

AbbVie's massive Humira discounts are stifling Netherlands biosimilars: report

AbbVie's massive Humira discounts are stifling Netherlands biosimilars: report

Fierce Pharma

Flag link:

First gene therapy to treat rare blood disease nears European approval

First gene therapy to treat rare blood disease nears European approval

Stat

beta-thalassemia

Flag link:

Drug Sampling and Testing: EMA Releases 20 Year Report, Will Expand Program to Biosimilars

Drug Sampling and Testing: EMA Releases 20 Year Report, Will Expand Program to Biosimilars

RAPS.org

Flag link:

As Brexit row become increasingly anarchic, is UK’s reputation with pharma suffering?

As Brexit row become increasingly anarchic, is UK’s reputation with pharma suffering?

Pharmaforum

Flag link:

Sanofi may airlift medicines into UK after Brexit

Sanofi may airlift medicines into UK after Brexit

Pharmaforum

Flag link:

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Endpoints

Flag link:

AZ’s diabetes drug Forxiga approved in EU for type 1 disease

AZ’s diabetes drug Forxiga approved in EU for type 1 disease

Pharmaforum

type 1 diabetes diabetes

Flag link:

Brexit delay offers biopharma more time to prepare for a no-deal

Brexit delay offers biopharma more time to prepare for a no-deal

BioCentury

Flag link:

EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet

EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet

Endpoints

rheumatoid arthritis

Flag link:

Roche clinches EU approval for MabThera in rare autoimmune indication — will it boost dwindling sales amid biosimiar competition?

Roche clinches EU approval for MabThera in rare autoimmune indication — will it boost dwindling sales amid biosimiar competition?

Endpoints

Flag link:

Merck notches fourth lung cancer approval in Europe for flagship Keytruda

Merck notches fourth lung cancer approval in Europe for flagship Keytruda

Endpoints

metastatic squamous non-small cell lung cancer

Flag link:

Pharma urges politicians to stop no-deal Brexit in today’s vote

Pharma urges politicians to stop no-deal Brexit in today’s vote

Pharmaforum

Flag link:

Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track

Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track

Xconomy

Bristol-Myers Squibb

multiple sclerosis

Flag link:

Bayer files prostate cancer drug darolutamide with EU regulators

Bayer files prostate cancer drug darolutamide with EU regulators

Pharmaforum

prostate cancer

Flag link:

Roche gets European approval for Tecentriq combo vs. lung cancer

Roche gets European approval for Tecentriq combo vs. lung cancer

Reuters

metastatic non-squamous non-small cell lung cancer

Flag link:

AbbVie, Akcea benefit from latest CHMP recommendations

AbbVie, Akcea benefit from latest CHMP recommendations

Biopharma Dive

Flag link:

Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz

Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz

Endpoints

Flag link:

Pages